1. Home
  2. APRE vs LDWY Comparison

APRE vs LDWY Comparison

Compare APRE & LDWY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APRE
  • LDWY
  • Stock Information
  • Founded
  • APRE 2006
  • LDWY 1990
  • Country
  • APRE United States
  • LDWY United States
  • Employees
  • APRE N/A
  • LDWY N/A
  • Industry
  • APRE Biotechnology: Biological Products (No Diagnostic Substances)
  • LDWY Advertising
  • Sector
  • APRE Health Care
  • LDWY Consumer Discretionary
  • Exchange
  • APRE Nasdaq
  • LDWY Nasdaq
  • Market Cap
  • APRE 8.3M
  • LDWY 8.9M
  • IPO Year
  • APRE 2019
  • LDWY 1991
  • Fundamental
  • Price
  • APRE $1.51
  • LDWY N/A
  • Analyst Decision
  • APRE Strong Buy
  • LDWY
  • Analyst Count
  • APRE 1
  • LDWY 0
  • Target Price
  • APRE $20.00
  • LDWY N/A
  • AVG Volume (30 Days)
  • APRE 50.3K
  • LDWY 2.0K
  • Earning Date
  • APRE 11-06-2025
  • LDWY 11-18-2025
  • Dividend Yield
  • APRE N/A
  • LDWY N/A
  • EPS Growth
  • APRE N/A
  • LDWY N/A
  • EPS
  • APRE N/A
  • LDWY 1.66
  • Revenue
  • APRE $841,012.00
  • LDWY $71,244,000.00
  • Revenue This Year
  • APRE N/A
  • LDWY N/A
  • Revenue Next Year
  • APRE N/A
  • LDWY N/A
  • P/E Ratio
  • APRE N/A
  • LDWY $3.09
  • Revenue Growth
  • APRE N/A
  • LDWY 187.12
  • 52 Week Low
  • APRE $1.37
  • LDWY $3.12
  • 52 Week High
  • APRE $5.01
  • LDWY $6.19
  • Technical
  • Relative Strength Index (RSI)
  • APRE 51.04
  • LDWY 47.02
  • Support Level
  • APRE $1.40
  • LDWY $4.69
  • Resistance Level
  • APRE $1.53
  • LDWY $5.08
  • Average True Range (ATR)
  • APRE 0.08
  • LDWY 0.25
  • MACD
  • APRE 0.01
  • LDWY -0.03
  • Stochastic Oscillator
  • APRE 67.77
  • LDWY 39.58

About APRE Aprea Therapeutics Inc. Common stock

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

About LDWY Lendway Inc. (DE)

Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two industries: Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.

Share on Social Networks: